Eli Lilly and Co at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good afternoon. I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Eli Lilly.
Lilly is a leading global pharmaceutical company with robust portfolio of fast-growing products and pipeline of first-in-class and/or best-in-class drugs. We think the company's earnings profile continues to look favorable when compared with those of its peers. Its margin profile represents one of the strongest expansion stories in pharma, with the potential for mid-teens EPS growth.
Lilly is entering a period of earnings and growth unencumbered by large loss of exclusivities and bolstered by multiple pipeline readouts of its first-in-class and best-in-class compounds. Therefore, we're thrilled to have with us today Patrik Jonsson, Senior Vice President of Eli Lilly & Company, President of Lilly Immunology, President of Lilly USA; and Chief Customer Officer, with us here today.
So Patrik, would you like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
